Burnham Institute

Following a $50 million pledge of support from T. Denny Sanford, the institute has been renamed the Sanford-Burnham Medical Research Institute.

After a delay due to California's budget difficulties, the Sanford Consortium for Regenerative Medicine has broken ground on a $126 million research facility intended to foster collaborations in the San Diego area.

The Burnham Institute's endowment declined 13 percent, due primarily to losses on investments, but its assets nearly doubled on grants from the State of Florida.

The institute recently hired two senior managers as it focuses greater attention on its drug commercialization and partnering efforts.

The collaboration will combine mass spec-based metabolite profiling expertise at Duke's Sarah W. Stedman Nutrition and Metabolism Center with complementary technologies at Burnham, particularly NMR-based methods.

The phosphoproteome, consisting of 2,546 phosphorylation sites and 1,603 phosphoproteins, provides a roadmap to better understand the mechanisms that control differentiation in stem cells and a basis for continued research leading to potentially new clinical therapies.

The institute's California and Florida campuses will join the oncology chemical screening consortium.

The research partnership with Magellan is the first with a private company for Burnham's Lake Nona, Fla., branch, which in May opened its permanent location in the Orlando area after inhabiting temporary digs since 2006.

Around the Regions

Premium

Maryland Biotechnology Investment Incentive Tax Credit, Maryland Stem Cell Research Fund, Washington State Life Sciences Discovery Fund, California Institute for Regenerative Medicine, Sanford Consortium for Regenerative Medicine, Missouri Life-Sci/Tech Tax Credits, Wisconsin Technology Venture Fund, New Jersey Edison Innovation Fund, University City Science Center QED

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.